Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

StreptAvax (ID Biomedical).

David McMillan1

  • 1The Queensland Institute of Medical Research, Bacterial Pathogenesis Laboratory, Brisbane, Australia. David.McMillan@qimr.edu.au

Current Opinion in Investigational Drugs (London, England : 2000)
|February 28, 2006
PubMed
Summary

ID Biomedical is developing StreptAvax, a subunit vaccine for group A streptococcal infections. Phase II clinical trials in adults were completed by January 2005, with pediatric trials planned for 2007.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chlamydia spp., Bordetella bronchiseptica, and Phascolarctid Gammaherpesvirus 1 and 2 Infections in Koalas (Phascolarctos cinereus) in South East Queensland, Australia: Detection in Healthy Individuals and Those with Signs of Respiratory or Other Disease.

Journal of wildlife diseases·2026
Same author

Dental Students' Anticipated Comfort and Willingness to Treat Specific Underserved Populations.

Journal of dental education·2026
Same author

Molecular basis for multidrug efflux by an anaerobic-associated RND transporter.

Nature communications·2025
Same author

Molecular basis for multidrug efflux by an anaerobic RND transporter.

bioRxiv : the preprint server for biology·2025
Same author

Disruption of the blood-brain barrier contributes to neurobehavioral changes observed in rheumatic heart disease.

Animal models and experimental medicine·2025
Same author

Discovery of ginisortamab, a potent and novel anti-gremlin-1 antibody in clinical development for the treatment of cancer.

mAbs·2023

Area of Science:

  • Immunology
  • Vaccinology
  • Microbial Infections

Background:

  • Group A Streptococcus (GAS) causes significant morbidity and mortality worldwide.
  • Development of effective vaccines against GAS remains a critical unmet medical need.
  • Subunit vaccines offer a promising approach to target GAS infections.

Purpose of the Study:

  • To evaluate the safety and immunogenicity of StreptAvax, a novel subunit vaccine candidate.
  • To assess the potential of StreptAvax in preventing group A streptococcal infections in adults.

Main Methods:

  • Phase II clinical trials were conducted in adult populations.
  • Data analysis from these trials was performed.
  • The study involved the administration and monitoring of the StreptAvax vaccine.

Main Results:

  • Analysis of Phase II clinical trial data in adults was completed by January 2005.
  • Specific efficacy and safety results are pending further analysis and reporting.
  • The vaccine candidate has progressed to the completion of adult trial data analysis.

Conclusions:

  • StreptAvax is a potential subunit vaccine targeting group A streptococcal infections.
  • Further clinical development, including pediatric trials, is planned.
  • The vaccine represents a step forward in addressing GAS-related diseases.

Related Experiment Videos